Traws Pharma Inc Cash Flow Conversion Efficiency
Traws Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, Traws Pharma Inc (TRAW) has a cash flow conversion efficiency ratio of -4.438x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.50 Million) by net assets ($1.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Traws Pharma Inc (2011–2025)
Cash flow conversion efficiency of Traws Pharma Inc from 2011 to 2025. This chart illustrates how Traws Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Traws Pharma Inc (TRAW) share price today for real-time trading data and today's change.
Traws Pharma Inc Cash Flow Conversion Ratio Explained
Traws Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Traws Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Traws Pharma Inc ranked by their cash flow conversion efficiency. Also see TRAW market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ignite Ltd
AU:IGN
|
0.302x |
|
ARK Resources Bhd
KLSE:7007
|
-0.760x |
|
Bindi Metals Ltd
AU:BIM
|
-0.099x |
|
STREAMPLAY STUDIO LTD.
F:GIX0
|
N/A |
|
Strategem Capital Corp
V:SGE
|
0.008x |
|
CARLSON INV. ZY 13
F:2HB
|
-0.001x |
|
UNITH LTD.
F:CM30
|
N/A |
|
Carmell Therapeutics Corporation
NASDAQ:CTCX
|
0.198x |
Annual Cash Flow Conversion Efficiency for Traws Pharma Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Traws Pharma Inc from 2011 to 2025. Review Traws Pharma Inc (TRAW) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-629.00K | $-18.18 Million | 28.911x | +2969.46% |
| 2024-12-31 | $-31.63 Million | $-29.79 Million | 0.942x | +156.06% |
| 2023-12-31 | $10.67 Million | $-17.93 Million | -1.680x | -191.93% |
| 2022-12-31 | $28.31 Million | $-16.29 Million | -0.576x | -36.22% |
| 2021-12-31 | $46.12 Million | $-19.49 Million | -0.423x | +88.69% |
| 2020-12-31 | $6.17 Million | $-23.07 Million | -3.737x | -107.62% |
| 2019-12-31 | $11.57 Million | $-20.83 Million | -1.800x | +57.28% |
| 2018-12-31 | $5.39 Million | $-22.70 Million | -4.213x | -292.10% |
| 2017-12-31 | $-10.86 Million | $-23.82 Million | 2.193x | +171.11% |
| 2016-12-31 | $5.13 Million | $-15.81 Million | -3.084x | -6.77% |
| 2015-12-31 | $10.84 Million | $-31.31 Million | -2.889x | -18.37% |
| 2014-12-31 | $23.62 Million | $-57.65 Million | -2.440x | -221.63% |
| 2013-12-31 | $80.90 Million | $-61.38 Million | -0.759x | -7255.60% |
| 2012-12-31 | $-158.31 Million | $1.63 Million | -0.010x | -110.08% |
| 2011-12-31 | $-138.42 Million | $-14.17 Million | 0.102x | -- |
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonu… Read more